期刊文献+

甲状腺激素抵抗综合征诊疗进展 被引量:1

Advances in diagnosis and treatment of thyroid hormone resistance syndrome
下载PDF
导出
摘要 甲状腺激素抵抗综合征(thyroid hormone resistance syndrome,RTH)是由甲状腺激素受体基因突变所致甲状腺激素作用的靶组织对甲状腺激素反应低下为特征的常染体显性遗传性疾病。临床表现变化多样,可呈甲亢、甲减或非毒性甲状腺肿,常被误诊从而采取不适当的治疗。减少误诊,关键在于提高对本病的认识。本文就近年来国内外对RTH诊疗新观点进行综述。 hTyroid hormone resistance syndrome (RTH) is an euchromosome dominant genetic disease, caused by the thyroid hormone receptor gene mutations. It is characterized by decreased responses of the target tissue to thyroid hormone. Its clinical manifestations, including hyperthyroidism, hypothyroidism and nontoxic goiter, are variable; and it is generally misdiagnosed resulting in inappropriate treatment. Increasing the knowledge for the disease is the key to reduce misdiagnosis. In this article, new perspectives on RTH diagnosis and treatment are reviewed.
作者 孔艳华
出处 《临床与病理杂志》 2016年第8期1229-1233,共5页 Journal of Clinical and Pathological Research
关键词 甲状腺激素抵抗综合征 基因诊断 生长抑素试验 RTHα thyroid hormone resistance syndrome (RTH) gene diagnosis somatostatin test RTHα
  • 相关文献

参考文献3

二级参考文献57

  • 1Dhillon KS,Cohan P,Kelly DF,et al.Treatment of hyperthyroidism associated with thyrotropin-secreting pituitary adenomas with iopanoic acid.J Clin Endocrinol Metab,2004,89:708-711.
  • 2Socin HV,Chanson P,Delemer B,et al.The changing spectrum of TSH-secreting pituitary adenomas:diagnosis and management in 43 patients.Eur J Endocrinol,2003,148:433-442.
  • 3Beck-Peccoz P,Persani L.Medical management of thyrotropin-secreting pituitary adenomas.Pituitary,2002,5:83-88.
  • 4Brucker-Davis F,Oldfield EH,Skarulis MC,et al.Thyrotropin-secreting pituitary tumors:diagnostic criteria,thyroid hormone sensitivity,and treatment outcome in 25 patients followed at the National Institutes of Health.J Clin Endocrinol Metab,1999,84:476-486.
  • 5Beck-Peccoz P,Brucker-Davis F,Persani L,et al.Thyrotropin-secreting pituitary tumors.Endocr Rev,1996,17:610-638.
  • 6Erem C,Hacihasanoglu A,Sari A,et al.A rare case and a rapid tumor response to therapy:dramatic reduction in tumor size during octreotide treatment in a patient with TSH-secreting pituitary macroadenoma.Endocrine,2004,25:141-145.
  • 7Kuhn JM,Arlot S,Lefebvre H,et al.Evaluation of the treatment of thyrotropin-secreting pituitary adenomas with a slow release formulation of the somatostatin analog lanreotide.J Clin Endocrinol Metab,2000,85:1487-1491.
  • 8Socin HV, Chanson P, Delemer B, et al. The changing spectrum of TSH secreting pituitary adenomas: diagnosis and management in 43 patients. Eur J Endocrinol, 2003,148:433-442.
  • 9Beck PP, Brucker DF, Persani L,et al. Thyrotropin-secreting pituitary tumors. Endocr Rev, 1996,17:610-638.
  • 10Jailer JW, Holub DA. Remission of Grave′s disease following radiotherapy of a pituitary neoplasm. Am J Med, 1960,28:497-500.

共引文献40

同被引文献5

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部